Table 3 General features of the trials which were included in this analysis.
Trials | Patients’ enrollment period | Type of DES in study group | Total no of patients treated with ZES (n) | Total no of patients treated with SES/PES or EES (n) |
|---|---|---|---|---|
ENDEAVOR III | 2004–2010 | SES | 307 | 108 |
ENDEAVOR IV | 2005–2006 | PES | 722 | 718 |
ISAR TEST 2 | 2006–2008 | SES | 339 | 335 |
PRODIGY | 2006–2008 | PES, EES | 500 | 500, 501 |
PROTECT | 2007–2008 | SES | 1174 | 1236 |
SORT OUT III | 2006–2009 | SES | 1162 | 1170 |
ZEST | 2006–2008 | SES, PES | 883 | 1762 |
PRISON III | 2007–2010 | SES | 150 | 154 |
ZOMAxx I | 2004–2005 | PES | 199 | 197 |
RESOLUTE | 2008 | EES | 1140 | 1152 |
TWENTE | 2008–2012 | EES | 695 | 692 |
TWENTE II | 2010–2012 | EES | 905 | 905 |
Total no of patients (n) | 8176 | 9430 |
